Dr. Mack Roach, III and Dr. Martin Spahn presented a debate on “Oligometastases: RP Is Experimental and Should Only Be Done in the Context of a Prospective Clinical Trial” versus “RP and SBRT to Bone Disease Is a Reasonable Management Strategy for Men with Oligomets” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: prostate cancer, oligometastatic disease, radical prostatectomy, stereotactic body radiation therapy
How to cite: Roach, Mack III and Spahn, Martin. “Debate: How Should We Manage Oligometastatic Disease?” Grand Rounds in Urology. October 14-16, 2016. Accessed Dec 2024. https://dev.grandroundsinurology.com/debate-how-should-we-manage-oligometastatic-disease
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Mack Roach III, MD, FACR, is a Professor of Radiation Oncology and Urology in the Department of Radiation Oncology at the University of California, San Francisco. He earned his MD from Stanford University School of Medicine. Dr. Roach chaired one of the most important large prospective randomized trials comparing different strategies for locally advanced prostate cancer. He has gained international recognition as an authority on treatment planning for prostate cancer and served as senior author for the guidelines for treatment planning published by the American College of Radiology. Dr. Roach is a member of several professional societies including the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, the Radiation Therapy Oncology Group, the NCI IMRT Working Group and American Joint Commission for Cancer Staging, the American Cancer Society Task Force for Cancer Screening Guidelines (Prostate Cancer), and the NCI Concept Evaluation Panel (Prostate Cancer Phase III Trials). He has co-authored more than 200 peer-reviewed journal articles, book chapters, and editorials. His major research interests include brachytherapy and the application of 3-D conformal and intensity-modulated radiotherapy (IMRT) treatment-planning technology as a major component of combined modality management of prostate cancer and other solid tumors.
